Literature DB >> 23796788

Effects of Newcastle disease virus vaccine antibodies on the shedding and transmission of challenge viruses.

Patti J Miller1, Claudio L Afonso, John El Attrache, Kristi M Dorsey, Sean C Courtney, Zijing Guo, Darrell R Kapczynski.   

Abstract

Different genotypes of avian paramyxovirus serotype-1 virus (APMV-1) circulate in many parts of the world. Traditionally, Newcastle disease virus (NDV) is recognized as having two major divisions represented by classes I and II, with class II being further divided into sixteen genotypes. Although all NDV are members of APMV-1 and are of one serotype, antigenic and genetic diversity is observed between the different genotypes. Reports of vaccine failure from many countries and reports by our lab on the reduced ability of classical vaccines to significantly decrease viral replication and shedding have created renewed interest in developing vaccines formulated with genotypes homologous to the virulent NDV (vNDV) circulating in the field. We assessed how the amount and specificity of humoral antibodies induced by inactivated vaccines affected viral replication, clinical protection and evaluated how non-homologous (heterologous) antibody levels induced by live NDV vaccines relate to transmission of vNDV. In an experimental setting, all inactivated NDV vaccines protected birds from morbidity and mortality, but higher and more specific levels of antibodies were required to significantly decrease viral replication. It was possible to significantly decrease viral replication and shedding with high levels of antibodies and those levels could be more easily reached with vaccines formulated with NDV of the same genotype as the challenge viruses. However, when the levels of heterologous antibodies were sufficiently high, it was possible to prevent transmission. As the level of humoral antibodies increase in vaccinated birds, the number of infected birds and the amount of vNDV shed decreased. Thus, in an experimental setting the effective levels of humoral antibodies could be increased by (1) increasing the homology of the vaccine to the challenge virus, or (2) allowing optimal time for the development of the immune response. Published by Elsevier Ltd.

Entities:  

Keywords:  Antigenicity; Humoral immunity; NDV; Newcastle disease virus; Transmission; Vaccines

Mesh:

Substances:

Year:  2013        PMID: 23796788     DOI: 10.1016/j.dci.2013.06.007

Source DB:  PubMed          Journal:  Dev Comp Immunol        ISSN: 0145-305X            Impact factor:   3.636


  37 in total

1.  Molecular and biological characterization of the immunological potency of Newcastle disease virus oil emulsion-inactivated vaccines prepared from field isolate obtained from vaccinated chickens outbreak.

Authors:  Mohammed Ismail Hassan; Mohamed Wael Abd El-Azeem; Abdullah Selim; Serageldeen Sultan
Journal:  Braz J Microbiol       Date:  2019-12-16       Impact factor: 2.476

2.  Atrophy of the lymphoid organs and suppression of antibody response caused by velogenic Newcastle disease virus infection in chickens.

Authors:  Wilfred Sunday Ezema; Didacus Chukwuemeka Eze; Shodeinde Vincent Olu Shoyinka; John Osita Arinze Okoye
Journal:  Trop Anim Health Prod       Date:  2016-09-19       Impact factor: 1.559

3.  Newcastle disease vaccination in captive-bred wild birds.

Authors:  C W C Gomes; G Funkler; I Andretta; M O Gonçalves; H F Santos; C E F Cruz
Journal:  Trop Anim Health Prod       Date:  2018-03-14       Impact factor: 1.559

4.  Genotypes II and VIId-based inactivated Newcastle disease vaccine reduces virus shedding.

Authors:  Nehal K Mahmoud; Ayman H El-Deeb; Mohammed M Emara; M A Abd El-Khaleck; Hussein A Hussein
Journal:  Virusdisease       Date:  2019-07-22

5.  Root-preferential expression of Newcastle virus glycoproteins driven by NtREL1 promoter in tobacco hairy roots and evaluation of oral delivery in mice.

Authors:  Narges Arkian Boroujeni; Somayeh Behjat Khatouni; Mohammad Javad Motamedi; Shaghayegh Afraz; Mahyat Jafari; Ali-Hatef Salmanian
Journal:  Transgenic Res       Date:  2022-01-10       Impact factor: 2.788

6.  Genotype VII.1.1-Based Newcastle Disease Virus Vaccines Afford Better Protection against Field Isolates in Commercial Broiler Chickens.

Authors:  Abdelmonem A A Dewidar; Walid H Kilany; Azza A El-Sawah; Salama A S Shany; Al-Hussien M Dahshan; Islam Hisham; Magdy F Elkady; Ahmed Ali
Journal:  Animals (Basel)       Date:  2022-06-30       Impact factor: 3.231

7.  Comparison of protection and viral shedding following vaccination with Newcastle disease virus strains of different genotypes used in vaccine formulation.

Authors:  Abdul Wajid; Asma Basharat; Tasra Bibi; Shafqat Fatima Rehmani
Journal:  Trop Anim Health Prod       Date:  2018-05-04       Impact factor: 1.559

8.  Synthesis and chemical characterization of several perfluorinated sialic acid glycals and evaluation of their in vitro antiviral activity against Newcastle disease virus.

Authors:  P Rota; N Papini; P La Rocca; M Montefiori; F Cirillo; M Piccoli; R Scurati; L Olsen; P Allevi; L Anastasia
Journal:  Medchemcomm       Date:  2017-06-05       Impact factor: 3.597

9.  Newcastle Disease in Backyard Poultry Rearing in the Northeastern States of India: Challenges and Control Strategies.

Authors:  Kekunguu Puro; Arnab Sen
Journal:  Front Vet Sci       Date:  2022-04-07

10.  Detection of Newcastle disease virus minor genetic variants by modified single-stranded conformational polymorphism analysis.

Authors:  Lukasz Rabalski; Krzysztof Smietanka; Zenon Minta; Boguslaw Szewczyk
Journal:  Biomed Res Int       Date:  2014-04-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.